AR061297A1 - Polimorfos de n-hidroxi -3- [4- [ [ [ 2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida - Google Patents

Polimorfos de n-hidroxi -3- [4- [ [ [ 2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida

Info

Publication number
AR061297A1
AR061297A1 ARP070102499A ARP070102499A AR061297A1 AR 061297 A1 AR061297 A1 AR 061297A1 AR P070102499 A ARP070102499 A AR P070102499A AR P070102499 A ARP070102499 A AR P070102499A AR 061297 A1 AR061297 A1 AR 061297A1
Authority
AR
Argentina
Prior art keywords
methyl
indol
hydroxy
phenyl
ethyl
Prior art date
Application number
ARP070102499A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061297(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR061297A1 publication Critical patent/AR061297A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

Se preparan por varios procedimientos formas polimorficas de base libre de (1) N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)etil]amino]-metil]fenil]-2E-2-propenamida y sales de la misma. Forma A, B, C, HA, HB y sus sales de maleato, tartrato, mesilato, acetato, benzoato, hemi-fumarato, fosfato, propionato, sulfato, hemi-succinato, lactato. Composicion farmacéutica.
ARP070102499A 2006-06-12 2007-06-08 Polimorfos de n-hidroxi -3- [4- [ [ [ 2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida AR061297A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80451706P 2006-06-12 2006-06-12
US88322407P 2007-01-03 2007-01-03

Publications (1)

Publication Number Publication Date
AR061297A1 true AR061297A1 (es) 2008-08-20

Family

ID=38832679

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102499A AR061297A1 (es) 2006-06-12 2007-06-08 Polimorfos de n-hidroxi -3- [4- [ [ [ 2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida

Country Status (29)

Country Link
US (1) US7989494B2 (es)
EP (2) EP2086930A2 (es)
JP (3) JP2009540006A (es)
KR (4) KR20090015968A (es)
CN (1) CN102584673B (es)
AR (1) AR061297A1 (es)
AU (1) AU2007257881B2 (es)
BR (1) BRPI0712993A2 (es)
CA (1) CA2650263A1 (es)
CL (1) CL2007001689A1 (es)
CR (1) CR10440A (es)
EA (1) EA017984B1 (es)
EC (1) ECSP088976A (es)
GE (1) GEP20115175B (es)
GT (1) GT200800280A (es)
IL (1) IL195015A (es)
MA (1) MA30511B1 (es)
ME (1) ME00529B (es)
MX (1) MX2008015900A (es)
MY (1) MY149337A (es)
NI (1) NI200800306A (es)
NO (1) NO20090135L (es)
PE (1) PE20080852A1 (es)
PH (1) PH12012501725A1 (es)
SM (1) SMP200900001B (es)
TN (1) TNSN08495A1 (es)
TW (2) TWI515179B (es)
UY (1) UY30406A1 (es)
WO (1) WO2007146716A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2032531B1 (en) * 2006-06-12 2016-02-10 Novartis AG Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
EP2117598A2 (en) * 2007-01-10 2009-11-18 Novartis AG Formulations of deacetylase inhibitors
WO2017032281A1 (zh) * 2015-08-21 2017-03-02 苏州晶云药物科技有限公司 帕比司他乳酸盐的新晶型
CN106866491B (zh) * 2015-12-10 2021-12-10 江苏豪森药业集团有限公司 帕比司他乳酸盐晶型ⅰ及其制备方法和用途
CN106866492B (zh) * 2015-12-10 2021-11-26 江苏豪森药业集团有限公司 帕比司他乳酸盐晶型ii及其制备方法和用途
WO2018092151A1 (en) * 2016-11-21 2018-05-24 Msn Laboratories Private Limited, R&D Center Process for the preparation of 2-(e)-n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) ethyl]amino]methyl]phenyl]-2-propenamide 2-hydroxypropanoic acid (1:1) and its polymorphs thereof
WO2018163114A1 (en) * 2017-03-10 2018-09-13 Shilpa Medicare Limited Amorphous panobinostat and its lactate salt
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
JP7409383B2 (ja) * 2019-08-20 2024-01-09 小野薬品工業株式会社 Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形
GB201913122D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ES2280597T3 (es) 2001-11-06 2007-09-16 Novartis Ag Combinacion de inhibidor de ciclooxigenasa-2/inhibidor de histona desacetilasa.
WO2003048774A1 (en) 2001-12-07 2003-06-12 Novartis Ag Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
MXPA05012464A (es) 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
JP2007501775A (ja) 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
AU2004273615B2 (en) 2003-09-23 2009-01-15 Novartis Ag Combination of a VEGF receptor inhibitor with a chemotherapeutic agent
EP2032531B1 (en) 2006-06-12 2016-02-10 Novartis AG Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Also Published As

Publication number Publication date
CN102584673A (zh) 2012-07-18
IL195015A (en) 2014-03-31
JP2015164968A (ja) 2015-09-17
TW201441190A (zh) 2014-11-01
EP2086930A2 (en) 2009-08-12
GT200800280A (es) 2015-11-24
AU2007257881A1 (en) 2007-12-21
KR20090015968A (ko) 2009-02-12
PE20080852A1 (es) 2008-08-19
MX2008015900A (es) 2009-03-06
KR20140142335A (ko) 2014-12-11
CL2007001689A1 (es) 2008-05-16
US7989494B2 (en) 2011-08-02
WO2007146716A2 (en) 2007-12-21
NO20090135L (no) 2009-03-12
US20090192210A1 (en) 2009-07-30
KR20160032264A (ko) 2016-03-23
CR10440A (es) 2011-08-22
IL195015A0 (en) 2009-08-03
EP2409967A1 (en) 2012-01-25
TWI453196B (zh) 2014-09-21
GEP20115175B (en) 2011-03-10
SMP200900001B (it) 2010-03-01
ECSP088976A (es) 2009-01-30
TWI515179B (zh) 2016-01-01
EA017984B1 (ru) 2013-04-30
ME00529B (me) 2011-10-10
JP2009540006A (ja) 2009-11-19
KR20150082690A (ko) 2015-07-15
AU2007257881B2 (en) 2011-06-16
NI200800306A (es) 2012-02-01
EA200802383A1 (ru) 2010-02-26
TNSN08495A1 (en) 2010-04-14
CN102584673B (zh) 2014-08-06
JP2013139476A (ja) 2013-07-18
UY30406A1 (es) 2008-01-31
TW200815344A (en) 2008-04-01
CA2650263A1 (en) 2007-12-21
WO2007146716A3 (en) 2009-07-30
MY149337A (en) 2013-08-30
BRPI0712993A2 (pt) 2012-04-17
MA30511B1 (fr) 2009-06-01
PH12012501725A1 (en) 2015-07-06
SMAP200900001A (it) 2009-01-14

Similar Documents

Publication Publication Date Title
AR061297A1 (es) Polimorfos de n-hidroxi -3- [4- [ [ [ 2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida
PE20090641A1 (es) Amidas heterociclicas
NO20090175L (no) Stabile laquinimod sammensetninger
NO20076498L (no) Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
JP2007016035A5 (es)
PE20061394A1 (es) Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
NZ592533A (en) METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR
EA200702498A1 (ru) N-(пиридин-2-ил)сульфонамидные производные
IL185035A0 (en) Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine
FR2900823B1 (fr) Nouvelle forme d'administration du racecadotril.
NO20091892L (no) Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre
JP2007508362A5 (es)
GEP20105125B (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) ethyl] amino] methyl] phenyl]-2e-2-propenamide
HRP20150569T1 (hr) 5-(fenil/piridinil-etinil)-2-piridin/2-pirimidin-karboksamidi kao modulatori za mglur5
DK1893589T3 (da) Substituerede N-benzo[d]isoxazol-3-yl-amin-derivater som inhibitorer af mGluR5-, serotonin-(5-HT) og noradrenalinreceptorer og deres anvendelse til fremstilling af lægemidler
FR2899316B1 (fr) Bras accroche-flammes d'une chambre de post-combustion
PE20080206A1 (es) Derivados de aril y heteroaril-etil-acilguanidina como inhibidores de renina
TW200626130A (en) 5-membered heterocycle derivatives
RS52050B (en) LIQUID PREPARATIONS Salts 4- [2- (4-METHYLPHENYLSULPHANYL) PHENYL] PIPERIDINE
ZA200809651B (en) Process for making salts of N-hydroxy-3[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
BRPI0415022A (pt) sais e polimorfos de um composto de indolinona substituìda com pirrol
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
AR054285A1 (es) Sal cristalina de derivado de 2-oxo-quinolina, agonista de beta 2 adrenergico, proceso y uso
EA200870157A1 (ru) Производные 2-карбамид-4-фенилтиазола, их получение и их применение в терапии

Legal Events

Date Code Title Description
FA Abandonment or withdrawal